Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure

被引:253
作者
Gueder, Guelmisal [1 ]
Bauersachs, Johann [1 ]
Frantz, Stefan [1 ]
Weismann, Dirk [1 ]
Allolio, Bruno [1 ]
Ertl, Georg [1 ]
Angermann, Christiane E. [1 ]
Stoerk, Stefan [1 ]
机构
[1] Univ Wurzburg, Dept Internal Med 1, Ctr Cardiovasc Med, D-97070 Wurzburg, Germany
关键词
aldosterone; cortisol; heart failure; hormones; prognosis; CARDIAC-HYPERTROPHY; BODY-MASS; RECEPTOR; DYSFUNCTION; MORBIDITY; DEATH; AGE; CHOLESTEROL; EPLERENONE; ANTAGONISM;
D O I
10.1161/CIRCULATIONAHA.106.653964
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-In patients with systolic heart failure, high levels of circulating aldosterone are associated with an adverse prognosis, and mineralocorticoid receptor blockade improves survival. The prognostic significance of cortisol that may also bind and activate the mineralocorticoid receptor in chronic heart failure is unknown. Methods and Results-Serum levels of cortisol and aldosterone were quantified in a prospective cohort study of 294 consecutive patients with chronic heart failure [48% were in New York Heart Association functional class III or IV; 58% had systolic heart failure]. During a median follow-up of 803 days (interquartile range, 314 to 1098), 79 patients died (27.3% mortality rate). Cortisol and aldosterone were independent predictors of increased mortality risk in Cox regression analyses adjusted for age, sex, New York Heart Association functional class, C-reactive protein, N-terminal pro-brain natriuretic peptide, sodium, and hypercholesterolemia. The hazard ratio for highest versus lowest tertile of cortisol was 2.72 [95% confidence interval [CI], 1.38 to 5.36; P = 0.004], and the hazard ratio for aldosterone was 2.19 (95% CI, 1.23 to 3.93; P = 0.008). Patients with both cortisol and aldosterone levels above the respective medians had a 3.4-fold higher mortality risk compared with subjects with both corticosteroids below the median (95% CI, 1.54 to 7.46; P = 0.0001). Addition of cortisol and aldosterone levels to the fully adjusted model significantly improved the discriminatory power [increase in Harrell's C-statistic from 0.80 (95% CI, 0.70 to 0.90) to 0.86 (95% CI, 0.79 to 0.94; P < 0.001 for change]. Conclusions-In patients with chronic heart failure, higher serum levels of both cortisol and aldosterone were independent predictors of increased mortality risk that conferred complementary and incremental prognostic value.
引用
收藏
页码:1754 / 1761
页数:8
相关论文
共 41 条
  • [21] Gender, age, and heart failure with preserved left ventricular systolic function
    Masoudi, FA
    Havranek, EP
    Smith, G
    Fish, RH
    Steiner, JF
    Ordin, DL
    Krumholz, HM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (02) : 217 - 223
  • [22] Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats
    Nagata, K
    Obata, K
    Xu, JL
    Ichihara, S
    Noda, A
    Kimata, H
    Kato, T
    Izawa, H
    Murohara, T
    Yokota, M
    [J]. HYPERTENSION, 2006, 47 (04) : 656 - 664
  • [23] THE NEUROHORMONAL HYPOTHESIS - A THEORY TO EXPLAIN THE MECHANISM OF DISEASE PROGRESSION IN HEART-FAILURE
    PACKER, M
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (01) : 248 - 254
  • [24] Pitt B, 1996, AM J CARDIOL, V78, P902
  • [25] ESCAPE OF ALDOSTERONE PRODUCTION IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION TREATED WITH AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR - IMPLICATIONS FOR THERAPY
    PITT, B
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 1995, 9 (01) : 145 - 149
  • [26] Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy - The 4E-left ventricular hypertrophy study
    Pitt, B
    Reichek, N
    Willenbrock, R
    Zannad, F
    Phillips, RA
    Roniker, B
    Kleiman, J
    Krause, S
    Burns, D
    Williams, GH
    [J]. CIRCULATION, 2003, 108 (15) : 1831 - 1838
  • [27] The effect of spironolactone on morbidity and mortality in patients with severe heart failure
    Pitt, B
    Zannad, F
    Remme, WJ
    Cody, R
    Castaigne, A
    Perez, A
    Palensky, J
    Wittes, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) : 709 - 717
  • [28] Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease
    Pitt, B
    Stier, CT
    Rajagopalan, S
    [J]. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2003, 4 (03) : 164 - 168
  • [29] The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction
    Pitt, B
    Williams, G
    Remme, W
    Martinez, F
    Lopez-Sendon, J
    Zannad, F
    Neaton, J
    Roniker, B
    Hurley, S
    Burns, D
    Bittman, R
    Kleiman, J
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2001, 15 (01) : 79 - 87
  • [30] Predictors of mortality and morbidity in patients with chronic heart failure
    Pocock, SJ
    Wang, DL
    Pfeffer, MA
    Yusuf, S
    McMurray, JJV
    Swedberg, KB
    Östergren, J
    Michelson, EL
    Pieper, KS
    Granger, CB
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 (01) : 65 - 75